Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 21 |
List of Tables | 19 | 3 |
List of Figures | 22 | 1 |
Introduction | 23 | 1 |
Global Markets Direct Report Coverage | 23 | 1 |
Head And Neck Cancer Squamous Cell Carcinoma Overview | 24 | 1 |
Therapeutics Development | 25 | 2 |
Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma Overview | 25 | 1 |
Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma Comparative Analysis | 26 | 1 |
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics under Development by Companies | 27 | 7 |
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics under Investigation by Universities/Institutes | 34 | 1 |
Head And Neck Cancer Squamous Cell Carcinoma Pipeline Products Glance | 35 | 4 |
Late Stage Products | 35 | 1 |
Clinical Stage Products | 36 | 1 |
Early Stage Products | 37 | 1 |
Unknown Stage Products | 38 | 1 |
Head And Neck Cancer Squamous Cell Carcinoma Products under Development by Companies | 39 | 10 |
Head And Neck Cancer Squamous Cell Carcinoma Products under Investigation by Universities/Institutes | 49 | 1 |
Head And Neck Cancer Squamous Cell Carcinoma Companies Involved in Therapeutics Development | 50 | 85 |
AB Science SA | 50 | 1 |
AbbVie Inc | 51 | 1 |
Accelerated Pharma, Inc. | 52 | 1 |
Acceleron Pharma, Inc. | 53 | 1 |
Adaptimmune Therapeutics Plc | 54 | 1 |
Advaxis, Inc. | 55 | 1 |
Altor BioScience Corporation | 56 | 1 |
Amgen Inc. | 57 | 1 |
AstraZeneca Plc | 58 | 1 |
AVEO Pharmaceuticals, Inc. | 59 | 1 |
Bayer AG | 60 | 1 |
Bionovis SA | 61 | 1 |
BioNTech AG | 62 | 1 |
Boehringer Ingelheim GmbH | 63 | 1 |
Bristol-Myers Squibb Company | 64 | 1 |
Calithera Biosciences, Inc. | 65 | 1 |
CEL-SCI Corporation | 66 | 1 |
Cellceutix Corporation | 67 | 1 |
Celldex Therapeutics, Inc. | 68 | 1 |
Centrose LLC | 69 | 1 |
Critical Outcome Technologies Inc. | 70 | 1 |
CytImmune Sciences, Inc. | 71 | 1 |
Daiichi Sankyo Company, Limited | 72 | 1 |
Eisai Co., Ltd. | 73 | 1 |
Eleven Biotherapeutics Inc. | 74 | 1 |
Eli Lilly and Company | 75 | 1 |
Etubics Corporation | 76 | 1 |
F. Hoffmann-La Roche Ltd. | 77 | 1 |
G&E Herbal Biotechnology Co., Ltd. | 78 | 1 |
GeneSegues Inc | 79 | 1 |
Genexine, Inc. | 80 | 1 |
Genmab A/S | 81 | 1 |
GlaxoSmithKline Plc | 82 | 1 |
Gliknik, Inc. | 83 | 1 |
Glycotope GmbH | 84 | 1 |
Hanmi Pharmaceuticals, Co. Ltd. | 85 | 1 |
Horizon Pharma Plc | 86 | 1 |
Immunomedics, Inc. | 87 | 1 |
Immunovative Therapies, Ltd. | 88 | 1 |
Incyte Corporation | 89 | 1 |
Infinity Pharmaceuticals, Inc. | 90 | 1 |
Innate Pharma S.A. | 91 | 1 |
Inovio Pharmaceuticals, Inc. | 92 | 1 |
IRX Therapeutics, Inc. | 93 | 1 |
Johnson &Johnson | 94 | 1 |
Kolltan Pharmaceuticals, Inc. | 95 | 1 |
Laboratoires Pierre Fabre SA | 96 | 1 |
Loxo Oncology, Inc. | 97 | 1 |
Mabion SA | 98 | 1 |
MacroGenics, Inc. | 99 | 1 |
Marsala Biotech Inc. | 100 | 1 |
Mateon Therapeutics Inc | 101 | 1 |
MedImmune LLC | 102 | 1 |
Merck &Co., Inc. | 103 | 1 |
Merck KGaA | 104 | 1 |
Merrimack Pharmaceuticals, Inc. | 105 | 1 |
Millennium Pharmaceuticals Inc | 106 | 1 |
Mirati Therapeutics Inc. | 107 | 1 |
Molecular Partners AG | 108 | 1 |
Molplex Ltd. | 109 | 1 |
NanoCarrier Co., Ltd. | 110 | 1 |
Novartis AG | 111 | 1 |
Oncobiologics, Inc. | 112 | 1 |
Oncolytics Biotech Inc. | 113 | 1 |
Onconova Therapeutics, Inc. | 114 | 1 |
OncoSec Medical Incorporated | 115 | 1 |
Ono Pharmaceutical Co., Ltd. | 116 | 1 |
Panacea Biotec Limited | 117 | 1 |
PCI Biotech Holding ASA | 118 | 1 |
Pfizer Inc. | 119 | 1 |
Reliance Life Sciences Pvt. Ltd. | 120 | 1 |
Sanofi | 121 | 1 |
Shanghai Henlius Biotech Co., Ltd. | 122 | 1 |
Shionogi &Co., Ltd. | 123 | 1 |
Sillajen Biotherapeutics | 124 | 1 |
Symphogen A/S | 125 | 1 |
SynCore Biotechnology Co., Ltd. | 126 | 1 |
Takara Bio Inc. | 127 | 1 |
Tara Immuno-Oncology Therapeutics LLC | 128 | 1 |
Transgene SA | 129 | 1 |
UbiVac, LLC | 130 | 1 |
VasGene Therapeutics, Inc. | 131 | 1 |
VentiRx Pharmaceuticals, Inc. | 132 | 1 |
Virttu Biologics Limited | 133 | 1 |
Vyriad Inc | 134 | 1 |
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Assessment | 135 | 30 |
Assessment by Monotherapy Products | 135 | 1 |
Assessment by Combination Products | 136 | 1 |
Assessment by Target | 137 | 12 |
Assessment by Mechanism of Action | 149 | 12 |
Assessment by Route of Administration | 161 | 2 |
Assessment by Molecule Type | 163 | 2 |
Drug Profiles | 165 | 534 |
ABBV-221 Drug Profile | 165 | 1 |
acalabrutinib Drug Profile | 166 | 3 |
AdIL-24 Drug Profile | 169 | 2 |
afatinib dimaleate Drug Profile | 171 | 13 |
AlloVax Drug Profile | 184 | 2 |
alpelisib Drug Profile | 186 | 3 |
ALT-803 Drug Profile | 189 | 3 |
AMG-319 Drug Profile | 192 | 1 |
Antibodies to Inhibit FRMD4A for Oncology Drug Profile | 193 | 1 |
Antisense Oligonucleotide to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma Drug Profile | 194 | 1 |
AV-203 Drug Profile | 195 | 3 |
avelumab Drug Profile | 198 | 6 |
axalimogene filolisbac Drug Profile | 204 | 16 |
AZD-1775 Drug Profile | 220 | 3 |
AZD-6738 Drug Profile | 223 | 1 |
AZD-9150 Drug Profile | 224 | 3 |
BMS-986016 Drug Profile | 227 | 2 |
BNV-003 Drug Profile | 229 | 1 |
buparlisib hydrochloride Drug Profile | 230 | 5 |
cabazitaxel Drug Profile | 235 | 2 |
capmatinib Drug Profile | 237 | 3 |
CB-1158 Drug Profile | 240 | 2 |
Cellular Immunotherapy for Oncology Drug Profile | 242 | 1 |
Cellular Immunotherapy to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma Drug Profile | 243 | 1 |
Cellular Immunotherapy to Target MAGE-A10 for Oncology Drug Profile | 244 | 2 |
cetuximab Drug Profile | 246 | 6 |
cetuximab biobetter Drug Profile | 252 | 2 |
cetuximab biosimilar Drug Profile | 254 | 1 |
cetuximab biosimilar Drug Profile | 255 | 1 |
cetuximab biosimilar Drug Profile | 256 | 1 |
cetuximab biosimilar Drug Profile | 257 | 1 |
cetuximab biosimilar Drug Profile | 258 | 1 |
cetuximab biosimilar Drug Profile | 259 | 1 |
cisplatin Drug Profile | 260 | 2 |
copanlisib hydrochloride Drug Profile | 262 | 4 |
COTI-2 Drug Profile | 266 | 8 |
CYT-6091 Drug Profile | 274 | 2 |
dalantercept Drug Profile | 276 | 4 |
Debio-1143 Drug Profile | 280 | 3 |
depatuxizumab Drug Profile | 283 | 1 |
DNA IL-12 Drug Profile | 284 | 8 |
DPV-001 Drug Profile | 292 | 2 |
DTP-348 Drug Profile | 294 | 1 |
durvalumab Drug Profile | 295 | 11 |
durvalumab + tremelimumab Drug Profile | 306 | 4 |
E-10A Drug Profile | 310 | 1 |
E-7046 Drug Profile | 311 | 1 |
EBC-46 Drug Profile | 312 | 1 |
EDC-2 Drug Profile | 313 | 1 |
EDE-1409 Drug Profile | 314 | 1 |
enoblituzumab Drug Profile | 315 | 2 |
epacadostat Drug Profile | 317 | 5 |
ETBX-041 Drug Profile | 322 | 1 |
everolimus Drug Profile | 323 | 11 |
ficlatuzumab Drug Profile | 334 | 3 |
futuximab + modotuximab Drug Profile | 337 | 3 |
ganetespib Drug Profile | 340 | 12 |
gedatolisib Drug Profile | 352 | 2 |
Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma Drug Profile | 354 | 1 |
GL-0817 Drug Profile | 355 | 1 |
glesatinib Drug Profile | 356 | 5 |
golvatinib tartrate Drug Profile | 361 | 2 |
GS-10 Drug Profile | 363 | 2 |
GSK-2636771 Drug Profile | 365 | 1 |
GSK-2849330 Drug Profile | 366 | 1 |
GSK-3174998 Drug Profile | 367 | 1 |
GX-051 Drug Profile | 368 | 1 |
HF-10 Drug Profile | 369 | 2 |
HSV-1716 Drug Profile | 371 | 3 |
human papillomavirus [serotypes 16] vaccine Drug Profile | 374 | 1 |
HylaPlat Drug Profile | 375 | 1 |
IC-1001 Drug Profile | 376 | 1 |
INCB-50465 Drug Profile | 377 | 1 |
INO-1400 Drug Profile | 378 | 1 |
INO-3106 Drug Profile | 379 | 1 |
INO-3112 Drug Profile | 380 | 2 |
interferon gamma-1b Drug Profile | 382 | 4 |
IPI-549 Drug Profile | 386 | 2 |
ipilimumab Drug Profile | 388 | 9 |
IRX-2 Drug Profile | 397 | 2 |
itacitinib adipate Drug Profile | 399 | 3 |
JS-001 Drug Profile | 402 | 1 |
JX-929 Drug Profile | 403 | 1 |
Kevetrin Drug Profile | 404 | 11 |
KGP-94 Drug Profile | 415 | 1 |
KTN-3379 Drug Profile | 416 | 4 |
lenvatinib mesylate Drug Profile | 420 | 13 |
Leukocyte Interleukin Drug Profile | 433 | 14 |
LGK-974 Drug Profile | 447 | 1 |
lirilumab Drug Profile | 448 | 4 |
LN-145 Drug Profile | 452 | 2 |
LOXO-101 Drug Profile | 454 | 4 |
lumretuzumab Drug Profile | 458 | 2 |
masitinib Drug Profile | 460 | 14 |
MEDI-0562 Drug Profile | 474 | 2 |
merestinib Drug Profile | 476 | 2 |
MGD-009 Drug Profile | 478 | 2 |
MIR-101 Drug Profile | 480 | 1 |
monalizumab Drug Profile | 481 | 4 |
Monoclonal Antibody to Target CD147 for Pancreatic Adenocarcinoma and Head and Neck Cancer Squamous Cell Carcinoma Drug Profile | 485 | 1 |
motolimod Drug Profile | 486 | 3 |
MP-0250 Drug Profile | 489 | 1 |
nilotinib Drug Profile | 490 | 6 |
nimotuzumab Drug Profile | 496 | 4 |
nivolumab Drug Profile | 500 | 33 |
NIZ-985 Drug Profile | 533 | 1 |
NP-001 Drug Profile | 534 | 1 |
olaparib Drug Profile | 535 | 9 |
Oncolytic Virus 1 to Target CD46 for Oncology Drug Profile | 544 | 1 |
Oncolytic Virus to Activate IFN-b for Hepatocellular Carcinoma and Head And Neck Cancer Squamous Cell Carcinoma Drug Profile | 545 | 1 |
palbociclib Drug Profile | 546 | 11 |
panitumumab Drug Profile | 557 | 5 |
patritumab Drug Profile | 562 | 2 |
pelareorep Drug Profile | 564 | 14 |
pembrolizumab Drug Profile | 578 | 37 |
PF-04518600 Drug Profile | 615 | 1 |
PF-06801591 Drug Profile | 616 | 1 |
picoplatin Drug Profile | 617 | 3 |
poziotinib Drug Profile | 620 | 2 |
prexasertib Drug Profile | 622 | 2 |
QR-206 Drug Profile | 624 | 1 |
Recombinant Peptide to Target EGFR for Oncology Drug Profile | 625 | 1 |
Recombinant Protein for Oncology Drug Profile | 626 | 1 |
rigosertib sodium Drug Profile | 627 | 10 |
S-488210 Drug Profile | 637 | 1 |
sacituzumab Drug Profile | 638 | 8 |
SB-01 Drug Profile | 646 | 1 |
seribantumab Drug Profile | 647 | 7 |
SF-1126 Drug Profile | 654 | 2 |
Small Molecules for Head and Neck Cancer Squamous Cell Carcinoma Drug Profile | 656 | 1 |
Small Molecules to Antagonize Endothelin B Receptor for Oncology Drug Profile | 657 | 1 |
Small Molecules to Inhibit 16S rRNA for Head And Neck Cancer Squamous Cell Carcinoma, Malaria and Oral Cancer Drug Profile | 658 | 1 |
Small Molecules to Inhibit CREB Protein for Head and Neck Cancer Squamous Cell Carcinoma Drug Profile | 659 | 1 |
Small Molecules to Inhibit IL-6 for Head and Neck Squamous Cell Carcinoma Drug Profile | 660 | 1 |
solarise Drug Profile | 661 | 1 |
Synthetic Peptide for Head and Neck Cancer Squamous Cell Carcinoma Drug Profile | 662 | 1 |
TAK-659 Drug Profile | 663 | 1 |
talimogene laherparepvec Drug Profile | 664 | 6 |